ReviewThrombosis journal2021
Current status of treatment of cancer-associated venous thromboembolism.
Review in Thrombosis journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- A Retrospective Analysis of Endovascular Stent Insertion for Malignant Superior Vena Cava Obstruction, Focusing on Anticoagulation Practices.Current oncology (Toronto, Ont.) · 2025Article
- Incidence and risk of arterial thromboembolism in cancer patients from a safety-net healthcare system.Journal of thrombosis and haemostasis : JTH · 2025Article
- Venous Thromboembolism in Cancer: Predictors of Recurrence and Bleeding in Patients on Direct Oral Anticoagulants.Journal of clinical medicine · 2025Article
- Clinical Characteristics and Incidence of Hemorrhagic Complications in Patients Taking Factor Xa Inhibitors in Spain: A Long-Term Observational Study.Journal of clinical medicine · 2024Article
- Deep Vein Thrombosis as a Complication of Gemcitabine-Capecitabine Chemotherapy in Adenocarcinoma of Gallbladder.Journal of blood medicine · 2024Article
- Complex Regional Pain Syndrome in Cancer Cases: Current Knowledge and Perspectives.International medical case reports journal · 2024Article
- Factors associated with in-hospital and outpatient survival of patients with different types of stage IV cancer and venous thromboembolism.The Journal of international medical research · 2023Article
- Abelacimab in Cancer-Associated Thrombosis: The Right Drug at the Right Time for the Right Purpose. A Comprehensive Review.Reviews in cardiovascular medicine · 2023Review
- Comparative Effectiveness of Anticoagulants in Patients With Cancer-Associated Thrombosis.JAMA network open · 2023Article
- Thrombogenesis-associated genetic determinants as predictors of thromboembolism and prognosis in cervical cancer.Scientific reports · 2023Article
- Article
- Map of thrombogenesis in viral infections and viral-driven tumours.Discover oncology · 2023Review
- Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.Journal for immunotherapy of cancer · 2023Article
- Anticoagulation and bleeding in the cancer patient.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Characteristics and Outcomes of Patients Consulted by a Multidisciplinary Pulmonary Embolism Response Team: 5-Year Experience.Journal of clinical medicine · 2022Article
- Article
- The Role of Direct Oral Anticoagulants in Cancer-Associated Thrombosis According to the Current Literature.Medicina (Kaunas, Lithuania) · 2021Review
- The significance of VTE in cancer: Introduction of the 'Spot the CLOT' series.Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2021Article
- Safety and Efficacy of Low Molecular Weight Heparin for Thromboprophylaxis in the Elderly: A Network Meta-Analysis of Randomized Clinical Trials.Frontiers in pharmacology · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with cancer are prone to develop venous thromboembolism (VTE) that is the second leading cause of mortality among them. Cancer patients with VTE may encounter higher rates of VTE recurrence and bleeding complications than patients without cancer. Treatment of established VTE is often complex in patients with cancer. Treatment of cancer-associated VTE basically comprises initial treatment, long-term treatment, treatment within 6 months, treatment beyond 6 months, treatment of recurrent VTE, and treatment in special situations. Decision of antithrombotic therapy, selection of anticoagulants, duration of anticoagulation, decision of adjuvant therapy, and adjustment of regimen in special situations are the major problems in the treatment of cancer-associated VTE. Therapeutic anticoagulation is the key of the key in the treatment of cancer-associated VTE. In addition to the efficacy and safety of low-molecular-weight heparin (LMWH) that has been fully demonstrated, direct oral anticoagulants (DOACs) are increasingly showing its advantages along with the accompanying concern in the treatment of cancer-associated VTE. The latest ASCO, ITAC and NCCN guidelines agree with each other on most aspects with respect to the treatment of cancer-associated VTE, whereas differ on a few issues. Encompassing recent randomized controlled trials, clinical trials, and meta-analyses, as well as the comparison of the latest authoritative guidelines including the NCCN, ASCO, and ITAC guidelines in this field, the objective of this review is to present current overview and recommendations for the treatment of cancer-associated VTE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.